UMBRALISIB for Marginal zone lymphoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 20 adverse event reports in the FDA FAERS database where UMBRALISIB was used for Marginal zone lymphoma.
Most Reported Side Effects for UMBRALISIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 47 | 16.0% | 2 | 5 |
| Nausea | 36 | 12.3% | 1 | 5 |
| Disease progression | 30 | 10.2% | 2 | 3 |
| Fatigue | 30 | 10.2% | 1 | 0 |
| Covid-19 | 16 | 5.5% | 3 | 13 |
| Nervous system disorder | 15 | 5.1% | 0 | 0 |
| Death | 14 | 4.8% | 14 | 4 |
| Asthenia | 13 | 4.4% | 1 | 2 |
| Off label use | 13 | 4.4% | 1 | 0 |
| Product dose omission issue | 12 | 4.1% | 0 | 3 |
| Anaemia | 11 | 3.8% | 0 | 0 |
| Decreased appetite | 11 | 3.8% | 1 | 2 |
| Pyrexia | 11 | 3.8% | 0 | 0 |
| Dizziness | 10 | 3.4% | 0 | 3 |
| Drug ineffective | 10 | 3.4% | 0 | 0 |
Other Indications for UMBRALISIB
Chronic lymphocytic leukaemia (66)
Non-hodgkin's lymphoma (50)
Follicular lymphoma (48)
Product used for unknown indication (42)
Diffuse large b-cell lymphoma (20)
B-cell lymphoma (18)
Lymphoma (9)
Other Drugs Used for Marginal zone lymphoma
RITUXIMAB (706)
IBRUTINIB (519)
LENALIDOMIDE (321)
OBINUTUZUMAB (188)
ETOPOSIDE (176)
BENDAMUSTINE (174)
CYCLOPHOSPHAMIDE (173)
IFOSFAMIDE (151)
METHOTREXATE (138)
DOXYCYCLINE (135)